Drugs / Rugonersen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT07605429 | Jun 2026 → Mar 2029 expected | Angelman syndrome | OHB Pediatrics Ltd. | Not yet recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07136454 | — | Angelman syndrome | Oak Hill Bio Ltd | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-09-09 | Oak Hill Bio Ltd | Results Oak Hill Bio Spotlights Publication Detailing Discovery and Initial Development of Rugonersen in Nucleic Acids Research oakhillbio.com ↗
The publication describes how rugonersen was discovered and details the strong pre-clinical data that supports clinical development. |
| 2025-07-11 | Oak Hill Bio Ltd | Results Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine oakhillbio.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rugonersen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07605429 ↗ |
| Modality | Antisense oligonucleotide | “Rugonersen is a selective synthetic 20-mer antisense oligonucleotide (ASO).” NCT07136454 ↗ |
| Route | Intrathecal | “intrathecally administered rugonersen” NCT07605429 ↗ |